U.S. markets closed

Big Rock Partners Acquisition Corp. (BRPA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
35.82+3.73 (+11.62%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
Previous Close32.09
Open31.00
Bid35.50 x 1200
Ask36.66 x 1000
Day's Range30.50 - 36.85
52 Week Range10.50 - 76.99
Volume12,634
Avg. Volume45,050
Market Cap96.293M
Beta (5Y Monthly)0.01
PE Ratio (TTM)N/A
EPS (TTM)-0.16
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • ACCESSWIRE

      Big Rock Partners Acquisition Corp. Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote "For" Extension Amendment Proposal

      NEW YORK, NY / ACCESSWIRE / April 7, 2021 / Big Rock Partners Acquisition Corp. (Nasdaq:BRPA) ("Big Rock") today clarified the procedure for stockholder redemptions in connection with Big Rock's special meeting of stockholders called for the purpose of approving an amendment to Big Rock's amended and restated certificate of incorporation to extend the date by which Big Rock has to consummate its initial business combination from April 23, 2021 to May 24, 2021 (the "extension amendment proposal").

    • NeuroRx Announces Zyesamiâ„¢ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
      PR Newswire

      NeuroRx Announces Zyesamiâ„¢ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir

      NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in a phase III multicenter clinical trial that will include the United States and multiple foreign countries. Aviptadil is being developed by NeuroRx as ZYESAMI™ in collaboration with Relief Therapeutics Holding, AG (SIX: RLF, OTCQB: RLFTF). The trial, designated as TESICO (Therapeutics for Severely Ill Inpatients with COVID-19), is funded by the US Government COVID-19 Therapeutics Response and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The TESICO protocol has been reviewed and approved as a phase III trial by the US Food and Drug Administration and will randomly allocate 640 participants to Aviptadil, Remdesivir, the combination of both drugs and placebo. Remdesivir is currently marketed as Veklury© by Gilead Sciences (Nasdaq: GILD). The primary endpoint of the trial will be participant recovery from respiratory failure over 90 days. Additional information will be supplied by the NIH when the trial randomizes its first patients.

    • /C O R R E C T I O N -- NeuroRx/
      PR Newswire

      /C O R R E C T I O N -- NeuroRx/

      NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMIâ„¢ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG (SIX:RLF, OTCQB:RLFTF). Across all patients and sites, ZYESAMIâ„¢ met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and also demonstrated a meaningful benefit in survival (P = < .001) after controlling for ventilation status and treatment site.